BCL2L1 and neoplasm: Similarly, Bcl-xL can also drive tumor progression in the presence of Bcl-2 protein-directed therapeutic resistance [88,89,90], while Mcl-1 amplification has been reported in lung and breast cancers [88] and, thus, carries equal levels of importance.